Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 774-781

  Weber, Michel ^a   Rabinowitz, Joseph ^b   Provost, Nathalie ^a   Conrath, Hervé ^a   Folliot, Sébastien ^a   Briot, Delphine ^a   Chérel, Yan ^c   Chenuaud, Pierre ^a   Samulski, Jude ^b   Moullier, Philippe ^a   Rolling, Fabienne ^a  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c LUNAM UNIVERSITÉ   (France)

Author keywords

AAV vectors; Dog; Gene transfer; GFP; Primate; Rat; Retina; Serotypes; Tropism

Indexed keywords

GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONGENITAL BLINDNESS; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSDUCTION; NONHUMAN; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; POLYMERASE CHAIN REACTION; RAT; RETINA DISEASE; RETINITIS PIGMENTOSA; REVIEW; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS SHEDDING;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ANIMALIA; CANIS FAMILIARIS; PRIMATES; RATTUS NORVEGICUS;

EID: 10744229842     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00098-4     Document Type: Article

References (45)

1. Bohl, D., Bosch, A., Cardona, A., Salvetti, A., and Heard, J. M. (2000). Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 95: 2793-2798.
2. Bosch, A., Perret, E., Desmaris, N., and Heard, J. M. (2000). Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 1: 63-70.
3. Daly, T. M., Vogler, C., Levy, B., Haskins, M. E., and Sands, M. S. (1999). Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Nalt. Acad. Sci. USA 96: 2296-2300.
4. Elliger, S. S., Elliger, C. A., Aguilar, C. P., Raju, N. R., and Watson, G. L. (1999). Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 6: 1175-1178.
5. Jung, S. C., et al. (2001). Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl. Acad. Sci. USA 98: 2676-2681.
6. Snyder, R. O., et al. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5: 64-70.
7. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 97: 13714-13719.
8. Xiao, X., et al. (2000). Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J. Virol. 74: 1436-1442.
9. Xiao, W., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73: 3994-4003.
10. Muramatsu, S., Mizukami, H., Young, N. S., and Brown, K. E. (1996). Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221: 208-217.
11. Chiorini, J. A., Yang, L., Liu, Y., Safer, B., and Kotin, R. M. (1997). Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71: 6823-6833.
12. Chiorini, J. A., Kim, F., Yang, L., and Kotin, R. M. (1999). Cloning and characterization of adeno-associated virus type 5. J. Virol. 73: 1309-1319.
13. Rutledge, E. A., Halbert, C. L., and Russell, D. W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72: 309-319.
14. Gao, G., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Nalt. Acad. Sci. USA 99: 11854-11859.
15. Chao, H., et al. (2000). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-623.
16. Chao, H., Monahan, P. E., Liu, Y., Samulski, R. J., and Walsh, C. E. (2001). Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol. Ther. 4: 217-222.
17. Davidson, B. L., et al. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97: 3428-3432.
18. Zabner, J., et al. (2000). Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74: 3852-3858.
19. Ali, R. R., et al. (1996). Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum. Mol. Genet. 5: 591-594.
20. Ali, R. R., et al. (1998). Adeno-associated virus gene transfer to mouse retina. Hum. Gene Ther. 9: 81-86.
21. Bennett, J., et al. (1999). Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc. Natl. Acad. Sci. USA 96: 9920-9925.
22. LaVail, M. M., et al. (2000). Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. USA 97: 11488-11493.
23. Liang, F. Q., et al. (2001). AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol. Ther. 3: 241-248.
24. Ali, R. R., et al. (2000). Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet, 25: 306-310.
25. Green, E. S., et al. (2001). Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of fgf-5 and fgf-18. Mol. Ther. 3: 507-515.
26. Lau, D., et al. (2000). Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Invest. Ophthalmol, Visual Sci. 41: 3622-3633.
27. Acland, G. M., et al. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28: 92-95.
28. Rabinowitz, J. E., et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76: 791-801.
29. Auricchio, A., et al. (2001). Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a model. Hum. Mol. Genet. 10: 3075-3081.
30. Yang, G. S., et al. (2002). Virus-mediated transduction of murine retina with adeno-associated virus: Effects of viral capsid and genome size. J. Virol. 76: 7651-7660.
31. Favre, D., et al. (2001). Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol. Ther. 4: 559-566.
32. Gal, A., et al. (2000). Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat. Genet. 26: 270-271.
33. Gu, S. M., et al. (1997). Mutations in RPE65 cause autosomal recessive childhood-onset severe retinal dystrophy. Nat. Genet. 17: 194-197.
34. Fisher, K. J., et al. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3: 306-312.
35. Xiao, W., et al. (1998). Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol. 72: 10222-10226.
36. Nathwani, A. C., et al. (2001). Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 97: 1258-1265.
37. Herzog, R. W., et al. (1999). Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5: 56-63.
38. Malik, A. K., et al. (2000). Kinetics of recombinant adeno-associated virus-mediated gene transfer. J. Virol. 74: 3555-3565.
39. Fisher, K. J., et al. (1996). Transduction with recombinant adeno-associated virus for gene therapy is limited by leading strand synthesis. J. Virol. 70: 520-532.
40. Ferrari, F. K., Samulski, T., Shenk, T., and Samulski, R. J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70: 3227-3234.
41. Kay, M. A., et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24: 257-261.
42. Wagner, J. A., et al. (2002). A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13: 1349-1359.
43. Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., and Chiorini, J. A. (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75: 6884-6893.
44. Salvetti, A., et al. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9: 695-706.
45. Duisit, G., et al. (2002). Five recombinant simian immunodeficiency virus (SIV) pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther. 6: 446-454.